Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.110
-0.120 (-3.72%)
At close: Mar 9, 2026, 4:00 PM EDT
3.090
-0.020 (-0.64%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Prelude Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 256 | 97 | 323 | 287 | 577 | 3,033 | |
| Market Cap Growth | 274.26% | -70.04% | 12.32% | -50.21% | -80.97% | - | |
| Enterprise Value | 223 | -39 | 93 | 65 | 259 | 2,798 | |
| Last Close Price | 3.23 | 1.27 | 4.27 | 6.04 | 12.45 | 71.55 | |
| PS Ratio | 24.76 | 13.82 | - | - | - | - | |
| PB Ratio | 4.20 | 0.74 | 1.36 | 1.47 | 2.02 | 14.30 | |
| P/TBV Ratio | 4.44 | 0.74 | 1.36 | 1.47 | 2.02 | 14.30 | |
| Debt / Equity Ratio | 0.31 | 0.14 | 0.07 | 0.01 | 0.01 | - | |
| Net Debt / Equity Ratio | -0.63 | -0.88 | -0.91 | -1.02 | -1.01 | -1.03 | |
| Net Debt / EBITDA Ratio | 0.31 | 0.84 | 1.65 | 1.64 | 2.57 | 3.75 | |
| Net Debt / FCF Ratio | 0.37 | 1.12 | 1.95 | 2.30 | 3.37 | 4.67 | |
| Asset Turnover | 0.07 | 0.03 | - | - | - | - | |
| Quick Ratio | 3.02 | 5.21 | 10.67 | 9.30 | 15.17 | 19.19 | |
| Current Ratio | 3.21 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | |
| Return on Equity (ROE) | -103.99% | -69.01% | -56.34% | -47.97% | -44.85% | -49.67% | |
| Return on Assets (ROA) | -51.82% | -38.54% | -33.19% | -29.38% | -26.89% | -29.93% | |
| Return on Capital Employed (ROCE) | -158.10% | -93.20% | -51.70% | -62.10% | -39.80% | -27.70% | |
| Earnings Yield | -43.00% | -131.47% | -37.74% | -40.16% | -19.35% | -1.88% | |
| FCF Yield | -38.58% | -107.16% | -34.25% | -30.18% | -14.87% | -1.54% | |
| Buyback Yield / Dilution | -2.37% | -25.60% | -27.41% | -2.87% | -269.03% | -647.86% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.